In a recent study, researchers
at the Hospital Clínico Universitario de Valladolid, Spain, took a
closer look at the records of RA patients who were treated with select
anti-TNF therapies between January 2011 and January 2012.
Researchers gathered demographic information and therapy assessments
from medical and pharmaceutical records. Staying on a treatment (also
called drug survival or persistence of therapy) was presumed to be an
overall marker of treatment success.
The primary
objective of the study was to assess how long patients stayed on a
particular anti-TNF drug and to identify potential predictors of drug
discontinuation. The overall goal of the study was to confirm whether
or not current clinical practice is appropriate in terms of the choice
of anti-TNF therapy for treating RA patients at this clinic.
Read this post in its entirety:
Enbrel vs. Remicade vs. Humira: Which Anti-TNF Drug Do RA Patients Stick With Longer?
No comments:
Post a Comment